Portage Biotech Stock Surges As It Prepares For Human Trial
1. PRTG stock surged 42.3% with high trading volume recently. 2. Portage Biotech reported strong preclinical data for PORT-7 (TT-4). 3. Data shows PORT-7 outperforms anti-PD1 in tumor models. 4. Combination therapy with PORT-7 indicates effective immune response. 5. Portage prepares for first-in-human trial with PORT-7.